Investing in the Future of Longevity – the Ketone Chapter
May 10, 2022 | London | 5pm BST (12pm EST)
In association with
Watch the webinar
About this webinar
The field of longevity has long been considered to be theoretical and one for the future, but that future is here now. The science of ketosis promises lucrative opportunities in a wide range of therapeutic areas, and the global keto market is expected to rise to $15 billion by 2027.
Juvenescence has brought together the leading experts in the ketone metabolism research field for a panel discussion on the revolution happening with ketones and the direction the research is leading the key players in this space. We cover how ketones can modulate fundamental aspects of human physiology, including glucose metabolism, brain function and heart health.
Juvenescence was founded with a mission to transform what aging means to the world. Science around aging is accelerating at an extraordinary pace so we’ve set out to further that science through a coalition of the best scientists, physicians and investors creating cutting-edge therapies and products that will empower people to chart their own path forward. Our company represents a modality-agnostic portfolio of therapies developed by seasoned drug developers augmented by machine learning. We have raised over $200MM to date and are organized around two major divisions: JuvRx (Drug Therapies) and JuvLife (NonRx IP-protected and clinically-studied food ingredients and dietary supplements).
Watch our webinar to get the experts’ insights on the latest research and development, hear from our founders, Dr. Greg Bailey and Jim Mellon on the opportunity areas in the market.
Join our webinar to get the experts’ insights on the latest research and developments, hear from our founders, Dr. Greg Bailey and Jim Mellon on the opportunity areas in the market, and participate in our live Q&A.
Lead Translational Scientist @The Buck Institute for Research on Aging
Dr. Stubbs is a world expert in exogenous ketone metabolism and its implications for performance, resilience and health-span. She completed her PhD in Metabolic Physiology at the University of Oxford, studying the metabolism and the application of exogenous ketone salts and esters. Brianna spent two years as Research Lead at a San Francisco start-up, where she helped to launch the world’s first commercially available ketone ester drink and set up a collaboration with the US Special Operations Command to investigate the effects of ketone drinks on physical and cognitive performance in extreme environments. Brianna is currently Lead Translational Scientist at The Buck Institute for Research on Aging where she’s part of a team focused on developing our understanding of ketone biology, the metabolic effects of novel exogenous ketones, and the translation of these findings into tools for implementation as part of a holistic approach to healthy aging.
Greg Bailey, a physician and financier, is co-founder and CEO of Juvenescence. The company aims to solve the problem of human aging by investing in technologies and treatments that are most likely to extend human lifespans and deliver high returns to shareholders. Greg is a serial entrepreneur in biotech and also serves as chairman of Portage Biotech, a publicly-traded oncology drug development company. Previously, he has been managing partner at Palantir Group, director at Medivation, and board member at Biohaven Pharmaceuticals Holding Company.
Professor of Medicine, Division of Molecular Medicine @University of Minnesota
Dr Peter Crawford is Professor of Medicine within the Division of Molecular Medicine at the University of Minnesota. His research focuses on the interplay between intermediary metabolism and the processes which drive obesity and cardiovascular disease.
Dr. Jonathan Little
Associate Professor, School of Health and Exercise Sciences @University of British Columbia
Dr. Jonathan Little is an Associate Professor in the School of Health and Exercise Sciences at the University of British Columbia Okanagan in Kelowna, BC, Canada. He is a former Canadian Institutes of Health Research (CIHR) New Investigator and Michael Smith Foundation for Health Research (MSFHR) Scholar, and current UBC Killam Accelerator Research Fellow whose main research interests focus on: 1) Optimizing diet and exercise interventions for the prevention, treatment, and reversal of type 2 diabetes; and 2) Understanding how lifestyle interventions impact the function of immune cells. He is the recipient of >$3M (CAD) in research grant funding as a principal investigator and has published over 140 peer- reviewed journal articles in the areas of exercise metabolism, nutrition, type 2 diabetes, obesity, and immunology. Ongoing studies in his lab are exploring how exogenous ketones impact glucose control, immune function, and cardiometabalic health.
John Newman, MD, PhD
Assistant Professor @The Buck Institute
John Newman, MD, PhD, is an assistant professor at the Buck Institute for Research on Aging and in the Division of Geriatrics at University of California San Francisco (UCSF). His career goal is to translate our expanding understanding of aging biology to improve the care and help maintain the independence of older adults. His research at the Buck Institute studies the molecular details of how diet and fasting regulate the genes and pathways that in turn control aging, focusing on the ketone body beta-hydroxybutyrate and how its molecular signaling activities involving epigenetics and inflammation regulate aging and memory in mice.
Chairman and co-founder of Juvenescence, Jim is an investor with interests in numerous industries. After leaving Oxford University, where he studied Philosophy, Politics and Economics, he worked in fund management companies around the world. Today Jim is focussed on biotech, clean food, and property, with other business interests managed by his family office, the Burnbrae Group. These interests include banking, mining and hotels. Jim has written several books, including Wake Up!, Juvenescence and the soon to be released Moo’s Law. Jim has established the Mellon Longevity Centre at Oxford, and is also an honorary fellow of Oriel College.